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ABSTRACT
Objective Most current cardiovascular disease (CVD) risk 
stratification tools are for people without CVD, but very 
few are for prevalent CVD. In this study, we developed and 
validated a CVD severity score in people with coronary 
heart disease (CHD) and evaluated the association 
between severity and adverse outcomes.
Methods Primary and secondary care data for 213 088 
people with CHD in 398 practices in England between 
2007 and 2017 were used. The cohort was randomly 
divided into training and validation datasets (80%/20%) 
for the severity model. Using 20 clinical severity indicators 
(each assigned a weight=1), baseline and longitudinal CVD 
severity scores were calculated as the sum of indicators. 
Adjusted Cox and competing- risk regression models were 
used to estimate risks for all- cause and cause- specific 
hospitalisation and mortality.
Results Mean age was 64.5±12.7 years, 46% women, 
16% from deprived areas, baseline severity score 1.5±1.2, 
with higher scores indicating a higher burden of disease. 
In the training dataset, 138 510 (81%) patients were 
hospitalised at least once, and 39 944 (23%) patients died. 
Each 1- unit increase in baseline severity was associated 
with 41% (95% CI 37% to 45%, area under the receiver 
operating characteristics (AUROC) curve=0.79) risk for 
1 year for all- cause mortality; 59% (95% CI 52% to 67%, 
AUROC=0.80) for cardiovascular (CV)/diabetes mortality; 
27% (95% CI 26% to 28%) for any- cause hospitalisation 
and 37% (95% CI 36% to 38%) for CV/diabetes 
hospitalisation. Findings were consistent in the validation 
dataset.
Conclusions Higher CVD severity score is associated 
with higher risks for any- cause and cause- specific 
hospital admissions and mortality in people with CHD. Our 
reproducible score based on routinely collected data can 
help practitioners better prioritise management of people 
with CHD in primary care.
INTRODUCTION
Cardiovascular disease (CVD) is the leading 
cause of death globally1 and accounts for 
more than one in four UK deaths.2 Coronary 
heart disease (CHD) is the most common 
CVD, accounting for nearly 9.5 million deaths 
worldwide in 2016.2 3 Around 15.5 million 
people had CHD in the USA by 2016, and 
Key questions
What is already known about this subject?
 ► The majority of current cardiovascular disease (CVD) 
risk stratification tools are for people without CVD 
with very few tools available for people with prev-
alent CVD.
 ► Coronary heart disease (CHD) is the most common 
type of CVD and a leading cause of death globally. 
In the UK, CHD is responsible for one death around 
every 8 min.
 ► It is estimated that nearly 2.3 million people are liv-
ing with CHD in the UK.
 ► The importance of assessing disease severity in 
people with CHD is well recognised, but validated 
CVD severity measures derived from routinely col-
lected health records are lacking, as are applica-
tions of such measures in primary care settings.
What does this study add?
 ► We developed a new CVD severity score incorpo-
rating 20 severity indicators using patients’ anony-
mised routinely collected electronic health records.
 ► In people with CHD, a 1- unit higher level of the se-
verity score was linked to up to 59% significantly 
higher risk of hospital admission or death.
How might this impact on clinical practice?
 ► We demonstrate the utility and validity of a CVD- 
specific severity measure in people with CHD using 
routinely collected data.
 ► Our severity measure has potential applications 
directly relevant to clinical practice and risk strat-
ification which informsadvanced decision making 
and provides a reproducible algorithm to other con-
ditions managed in primary care.
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2.3 million people in the UK by 2018 at a prevalence of 
3%.2 4
Most currently available prospective cardiovascular 
(CV) risk stratification tools are for people without known 
CVD,5 including QRISK and Framingham scores6 7 with 
very few tools available to help assess the disease severity 
in people with existing CVD. In the context of this paper, 
we adopt the definition of severity of clinical condi-
tions as the manifestation of the progression of under-
lying disease processes with implications on healthcare 
resources utilisation, multimorbidity and mortality.8 9
To our knowledge, no established CVD severity scores 
for primary care patients with CHD exist, and previous 
cohort studies are sparse,10 with the majority of literature 
based on clinical trials of different sizes or using various 
sources of data mainly captured in secondary care facil-
ities. Such attempts either focused primarily on existing 
scores/indices (such as SYNTAX,11 Gensini,12 the Duke 
CAD Prognostic Severity Index13 and CAD- RADS14); 
the prevalence of multivessel disease; or the degree of 
coronary stenosis and/or lesions.13–19 However, existing 
scores are not designed for primary care settings and only 
subserve a small minority of patients. While other scores 
would need invasive interventions that may not be indi-
cated (or in minority of patients) and therefore resources 
needed for such information would be limited and not 
routinely available in primary care settings. CV- specific 
severity measures derived from routine clinical records 
of CVD progression are needed and could support prac-
titioners to provide better clinical management as well 
as help healthcare policy makers and planners in devel-
oping services and allocating resources.
Since all of the above approaches rely on data that are 
not necessarily available in routine primary care health 
records for all patients, they are not useful for informing 
decisions at a primary care or public health levels based 
on identifying patients at risk of adverse outcomes. 
Currently available routinely collected electronic health 
records (EHRs) provide a platform for developing 
disease severity indices that are informative in stratifying 
CHD populations.
We, therefore, developed a severity score derived from 
routine EHR in UK primary care to stratify CHD popula-
tions in terms of CVD severity as a means of risk stratifi-
cation. We aimed to: (1) develop and internally validate 
baseline and longitudinal CV severity scores in individ-
uals with CHD and (2) assess what the score adds to the 
predictive value of sociodemographic variables for the 
risks for all- cause and cause- specific hospitalisation and 
mortality outcomes.
METHODS
Data source and patient population
In this retrospective cohort study, we used the GOLD 
database of the Clinical Practice Research Datalink 
(CPRD). The CPRD is one of the world’s largest EHR 
databases providing anonymised medical data (including 
demographics, tests, diagnoses, referrals and prescrip-
tions) and is broadly representative of the UK popula-
tion.20 21 CPRD provides data linkage to additional data-
sets and disease registries. We used the following linkages: 
Hospital Episodes Statistics Admitted Patient Care(HES 
APC), Office for National Statistics (ONS) cause- specific 
mortality data and index of multiple deprivation (IMD). 
The IMD used in our study is recorded at the level of the 
patient’s residential postcode in England and is a score 
calculated as the weighted sum of 37 individual indicators 
organised across seven domains of deprivation: access to 
housing and services, crime, employment, education, 
income, finance and living environment.22 Theemploy-
ment and income deprivation domains contribute the 
most weight to the overall index.
Patients with CHD (defined as patients with ≥1 CHD 
code listed in online supplemental table S1) aged 
≥35 years and registered in linked general practices in 
England were identified between 1 March 2007 and 31 
March 2017. The validity of CVD diagnoses in CPRD data 
has been acknowledged previously.23 For each patient, 
the index date was defined as the earliest CHD diagnosis 
date. Patients were followed up until the earliest date of: 
developing an outcome; leaving the general practice; 
study end (31 March 2017); or death. By definition of 
multiple event models (as in Poisson models), devel-
oping the outcome of interest was not a censor point for 
those analyses. The final cohort of eligible patients was 
randomly split into training (80%) and validation (20%) 
datasets. The 20% split of the dataset was used to repli-
cate the analyses performed in the training dataset as a 
validation.
Severity scores
A scoping review of indicators and markers of disease 
severity in people with CHD combined by the team’s clin-
ical expert opinion on CVD severity was used to identify 
clinically relevant CV severity indicators in people with 
CHD. A total of 20 CV indicators were used: hypertension; 
hyperlipidaemia; proteinuria/albuminuria; end- stage 
renal disease; peripheral vascular disease; stable angina; 
cardiac arrest; atrial fibrillation/supraventricular tachy-
cardia; myocardial infarction/acute coronary syndrome; 
heart valve disease; endocarditis; myocarditis; cardiomyo-
pathy; pericardial disease; ventricular tachycardia/fibril-
lation; congestive heart failure; CV procedures; transient 
ischaemic attack or stroke; diabetes; and pacemaker/
defibrillator use. The Read codes for severity indicators 
recorded in CPRD were identified using the (pcdsearch) 
Stata command.24
Based on the timing of severity indicators, the 
severity score was calculated as the sum of indica-
tors (each assigned weight=1) recorded at preindex 
(on/before first CHD diagnosis date, ie, baseline 
severity) or postindex (after first CHD diagnosis, ie, 
longitudinal severity) windows (online supplemental 
table S2). For preindex scores, indicators recorded in 
three look- back windows were considered: ever before 
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(unlimited look- back window), up to 10 and up to 5 years 
before index. This aimed to investigate the effects of 
varying the length of the preindex record on the model 
fitness in order to identify the optimal look- back window 
for prediction of future adverse outcomes but simulta-
neously considering the data quality that improved in 
recent years. For postindex scores, indicators recorded 
annually in years 1–10 after index date were considered, 
each combined with each of the three look- back windows. 
Postindex scores aimed to assess the trends of CV severity 
over time and how the risk for adverse outcomes change 
up to 10 years after CHD diagnosis.
Covariates
Age at baseline, gender, socioeconomic status (IMD 2015 
quintiles 1–5 or unknown) and ethnicity (white, black, 
Asian, mixed, other or unknown).
Outcomes
Primary outcome was all- cause mortality. Secondary 
outcomes were: clustered CV/ diabetes- related mortality; 
any- cause hospitalisation; clustered CV/diabetes- related 
hospitalisation; and aggregated any- cause hospitalisation 
and mortality.
Data analyses
Cox proportional hazards regression models were fitted 
to estimate HRs and 95% CIs to assess the relationship 
between the calculated severity score and outcomes in the 
training dataset, with the inclusion of sociodemographic 
covariates. We developed both single event and multiple 
failure- time events models. The single event models were 
used to assess the risk for 1- year, 3- year, 5- year and 10- year 
for each of all- cause mortality and clustered CV/diabetes- 
related mortality. We experimented with different predic-
tion horizons (1–10 years) to determine how the risks for 
adverse outcomes change over time after CHD diagnosis. 
A sensitivity analysis was conducted with the outcome 
being 1- year all- cause mortality excluding events in first 
30 days, as these events may be related to the index event. 
Multiple failure- time events models were fitted, using 
the Breslow method to handle tied failures, for the risk 
of recurrent all- cause hospitalisations. Poisson regres-
sion models were used to estimate the unadjusted and 
adjusted incidence rate ratios (IRRs) and 95% CIs for 
the association between severity score in a given year 
and the number of all- cause hospital admissions in the 
following year annually for 1–10 years after index date. 
Competing risk analysis was conducted to estimate the 
subhazard ratio (SHR) and 95% CIs for the risk for 
1- year any- cause hospitalisation and 1- year CV/diabetes- 
related hospitalisation while accounting for deaths as a 
competing event. Single event Cox models were used 
to assess the risk for the 1–10 year aggregated any- cause 
hospitalisation and mortality outcome. Likelihood ratio 
(LR) tests were fitted to assess the statistical significance 
of adding each of the developed severity scores (models 
2, 3 or 4) to the demographics only model (model 1) in 
improving the models fit for predicting the outcomes. We 
also modelled the unlimited severity score divided into 
four categories: no severity (score=0) as a referent group; 
low severity (score=1–2); moderate severity (score=3–4); 
and high severity (score ≥5) to assess the strength of asso-
ciations between the score and outcomes. Kaplan- Meier 
survivor function plots for hospitalisation, and mortality 
outcomes were fitted using severity score categories. All 
fitted models per outcome are summarised in online 
supplemental table S3.
The severity scores’ calibration was tested using three 
methods: Somer’s D25; comparing the survival curves for 
a given risk group26; and comparing the observed and 
predicted survival probabilities in prognostic groups 
derived by the severity score’s cut points.27 Poisson 
regression, multiple event regression and competing risk 
models’ goodness of fit was assessed using the Akaike 
information criterion (AIC), where smaller AIC indicates 
a better fit of the data than larger AIC.28 The predictive 
value of the single event survival models was assessed 
using Gönen and Heller’s K concordance statistic (C- sta-
tistic), a measure of the area under a receiver operating 
characteristics (AUROC) curve for censored data.29 
C- statistic ranges between 0 and 1, where value close to 
1 indicates an accurate model with high separation of 
subjects with different outcomes.30 31 Hence, AUROCs 
are reported for all models except for the three afore-
mentioned models where it was not possible to calculate 
them. Given the need to use two different postestima-
tion measures (AIC and C- statistic), both were estimated 
and reported. The proportional hazards assumption was 
assessed using Schoenfeld residuals. All analyses were 
replicated in the 20% split of the data as a validation. 
Data were analysed using Stata software V.15.32 The study 
is reported according to the RECORD checklist.
Patient and public involvement and engagement (PPIE)
We invited patients with CHD to a PPIE meeting. The 
participants agreed on the importance and the relevance 
of the study and suggested the need to raise the awareness 
about disease severity and to further highlight the fact 
that it involves several body organs and other conditions. 
Their perceptions about disease severity and indicators 
of increased disease severity varied between ‘not thought 
about disease severity before’ to listing a few indicators 
they considered relevant, such as declined physical func-
tion. The participants shared their views on approaches 
for disseminating the results via general practices and 
online social media outlets. We plan to disseminate the 
study findings widely to patient communities via local 
heart centres and general practices, and our social media 
platforms.
RESULTS
Overall, 213 088 patients with CHD were included 
(training dataset: n=1 70 395, validation dataset: 
n=42 693). Mean (±SD) age was 64.5±12.7 years; 46% 
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were women; 89% white; 16% from deprived areas 
(table 1). The ever before (unlimited) severity score 
ranged between 0 and 10 (mean±SD: 1.5±1.2), the 
10- year before score between 0 and 10 (1.4±1.1) and the 
5- year score between 0 and9 (1.2±1.0) (figure 1). The 
event rates show an increasing event rate with 1- unit 








Age (years), mean(±SD) 64.5 (±12.7) 64.5 (±12.7) 64.5 (±12.8)
Gender (female) 98 041 (46.0) 78 444 (46.0) 19 597 (46.0)
Number of general practices 398 398 395
Mean follow- up (years), mean (±SD) 9.4 (±6.0) 9.4 (±6.0) 9.4 (±6.0)
Ethnicity
  White 189 272 (88.8) 151 356 (88.83) 37 916 (88.81)
  Black 2017 (0.95) 1626 (0.95) 391 (0.92)
  Asian 4933 (2.32) 3940 (2.31) 993 (2.33)
  Mixed 596 (0.28) 485 (0.28) 111 (0.26)
  Other 1649 (0.77) 1299 (0.76) 350 (0.82)
  Unknown 14 621 (6.86) 11 689 (6.86) 2932 (6.87)
Levels of social deprivation (IMD quintiles)
  Q1 (least deprived) 45 719 (21.5) 36 770 (21.6) 8949 (21.0)
  Q2 49 251 (23.1) 39 472 (23.2) 9779 (22.9)
  Q3 44 543 (20.9) 35 474 (20.8) 9069 (21.2)
  Q4 39 032 (18.3) 31 141 (18.3) 7891 (18.5)
  Q5 (most deprived) 34 412 (16.2) 27 435 (16.1) 6977 (16.3)
  Unknown 131 (0.1) 103 (0.1) 28 (0.1)
Severity indicators at baseline
  Hypertension 109 455 (51.4) 87 422 (51.3) 22 033 (51.6)
  Hyperlipidaemia 33 309 (15.6) 26 553 (15.6) 6756 (15.8)
  Diabetes 22 763 (10.7) 18 079 (10.6) 4684 (11.0)
  Proteinuria/albuminuria 4299 (2.0) 3401 (2.0) 898 (2.1)
  End- stage renal disease (ESRD) 623 (0.3) 490 (0.3) 133 (0.3)
  Peripheral vascular disease (PVD) 7220 (3.4) 5793 (3.4) 1427 (3.3)
  Stable angina 30 838 (14.5) 24 667 (14.5) 6171 (14.5)
  Cardiac arrest 1180 (0.6) 919 (0.5) 261 (0.6)
  AF/SVT 17 810 (8.4) 14 270 (8.4) 3540 (8.3)
  Myocardial infarction/ACS 38 451 (18.0) 30 715 (18.0) 7736 (18.1)
  Heart valve disease 3587 (1.7) 2891 (1.7) 696 (1.6)
  Endocarditis 292 (0.1) 235 (0.1) 57 (0.1)
  Myocarditis 157 (0.1) 118 (0.1) 39 (0.1)
  Cardiomyopathy 1105 (0.5) 886 (0.5) 219 (0.5)
  Pericardial disease 682 (0.3) 534 (0.3) 148 (0.3)
  Ventricular tachycardia/fibrillation 675 (0.3) 519 (0.3) 156 (0.4)
  Cardiovascular procedures 10 270 (4.8) 8248 (4.8) 2022 (4.7)
  TIA/stroke 18 783 (8.8) 15 053 (8.9) 3730 (8.7)
  Pacemaker or defibrillator use 2460 (1.2) 1972 (1.2) 488 (1.1)
  Congestive heart failure 10 888 (5.1) 8645 (5.1) 2243 (5.3)
All data are presented as count (%) unless otherwise stated.
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increase in baseline unlimited severity score (online 
supplemental table S4).
All-cause mortality
Overall, 39 944 deaths occurred in 170 395 patients (23%), 
of which 1988 (1%) deaths occurred in the first year (of 
which, 544 events occurred within 30 days) and 24 130 
(14%) by the 10th year after index. Higher levels of the 
severity score was positively associated with increasing risk 
for all- cause mortality (figure 2A,B). For each one- unit 
increase of the ever before (unlimited) severity score, 
the risks for both 1- year and 3- year all- cause mortality 
increased by 41% (1- year adjusted HR 1.41 (95% CI 
1.37 to 1.45, AUROC=0.7912); 3- year HR: 1.41 (95% CI 
1.39 to 1.43, AUROC=0.7882), 5 years by 39% (HR: 1.39, 
95% CI 1.37 to 1.40, AUROC=0.7872) and 10 years by 
35% (HR: 1.35, 95% CI 1.34 to 1.36, AUROC=0.7849). 
In comparison, the sociodemographics- only model 
(model 1) had AUROC of 0.7865 for 1- year all- cause 
mortality, indicating that adding the severity score slightly 
improved the models predictive value (LR test p<0.0001). 
The 1–10 year postindex scores showed similar results for 
risk of all- cause mortality (online supplemental table S5). 
The sensitivity analysis of excluding deaths in the first 30 
days showed similar findings as the primary analysis.
CV/diabetes-related mortality
Each one unit increase of the unlimited severity score was 
associated with significantly higher risks at 1, 3, 5 and 10 
years: HRs: 1.59 (95% CI 1.52 to 1.67, AUROC=0.8030); 
1.61 (95% CI 1.56 to 1.65, AUROC=0.8041); 1.60 (95% 
CI 1.56 to 1.63, AUROC=0.8024); 1.57 (95% CI 1.55 to 
1.60, AUROC=0.8010), respectively (table 2). For 1- year 
CV/diabetes- related mortality, adding the severity score 
improved the models predictive value (LR test p<0.0001) 
in comparison to model 1 (AUROC=0.7962). The 
1–10 year postindex scores showed similar trends (online 
supplemental table S6).
All-cause hospitalisation
Overall, 138 510 (81% of patients) admissions occurred 
in 170 395 individuals, of which 43 023 (25%) and 127 358 
(75%) occurred within 1 and 10 years after index, respec-
tively. Higher severity showed a greater risk for future all- 
cause hospitalisation (figure 2E,F). Multiple failure anal-
ysis showed an increased risk for recurrent hospitalisation 
for one- unit increase in score (HR: 1.33, 95% CI 1.29 to 
1.37) (online supplemental table S7) . For Poisson regres-
sion, unadjusted IRRs for the count of next year's hospi-
talisations ranged between 1.43 (95% CI 1.43 to 1.44) in 
1 year after index to 1.37 (95% CI 1.35 to 1.40) in 10 years 
after index. When also adjusted for covariates, the model 
fit improved marginally with IRRs ranging between 1.39 
(95% CI 1.39 to 1.40) and 1.37 (95% CI 1.34 to 1.40) 
for the same period (online supplemental table S8). The 
competing risks analysis showed each one- unit increase 
of the ever severity score was associated with 27% higher 
risks for 1- year any- cause hospitalisation (SHR: 1.27 (95% 
1.26 to 1.28)) improving the predictive value provided 
by regression models only including sociodemographic 
variables – model 1 (LR test p<0.0001) (table 3).
CV/diabetes-related hospitalisation
Overall, 30 282 (18% of patients) events occurred within 
1 year in 170 395 patients with CHD. For 1- year CV/
diabetes- related admissions outcome, each one- unit 
increase in the ever before severity score was associated 
with SHR: 1.37 (95% CI 1.36 to 1.38) improving the 
predictive value provided by model 1 (LR test p<0.0001) 
(table 3), and it performed better than the any- cause 
admissions model.
Aggregated any-cause hospitalisation and mortality
Each one- unit increase in ever before severity score 
was associated with increased risks by 27% (26%–28%, 
AUROC=0.6271) at 1 year. Similar trends were observed 
at 3, 5 and 10 years after index (online supplemental 
table S9).
A summary of the estimated AIC and AUROC for 
fitted models is presented in table 4. For models where 
it was possible to estimate both AIC and AUROC, a 
summary is plotted in online supplemental figure S1, 
and there was a trend consistently showing improved 
model performance predicting cause- specific outcomes 
Figure 1 Distribution of baseline cardiovascular (CV) 
severity scores in the training and validation datasets.
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Figure 2 Kaplan- Meier survivor plots for adverse outcomes by CV severity score categories – training dataset. CV, 
cardiovascular; DM, diabetes mellitus. The survival probability scale (Y- axis) for 1- year and 3- year mortality was curtailed for 
improved differentiation of survival plots.
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Table 2 Survival models for 1, 3, 5 and 10- year CV/diabetes- related mortality using baseline scores—HR (95% CI)—training 
dataset
Predictor(s) 1 year 3 years 5 years 10 years
Model 1 Age 1.13 (1.12 to 1.14) 1.13 (1.13 to 1.14) 1.13 (1.13 to 1.13) 1.13 (1.12 to 1.13)
Gender (F) 0.74 (0.63 to 0.87) 0.70 (0.64 to 0.77) 0.70 (0.65 to 0.75) 0.71 (0.68 to 0.75)
IMD (vs least deprived)         
  Q5 (most deprived) 1.33 (1.02 to 1.73) 1.47 (1.27 to 1.71) 1.46 (1.30 to 1.64) 1.58 (1.46 to 1.72)
Ethnicity (vs white)         
  Black 2.80 (1.44 to 5.43) 2.08 (1.35 to 3.21) 1.79 (1.24 to 2.58) 1.45 1.08 to 1.95)
  Asian 1.97 (1.16 to 3.35) 1.80 (1.31 to 2.48) 1.72 (1.33 to 2.22) 1.38 1.13 to 1.70)
  Mixed – 1.81 (0.75 to 4.35) 1.57 (0.75 to 3.30) 0.81 0.39 to 1.70)
  Other 1.81 (0.81 to 4.05) 1.40 (0.83 to 2.37) 1.30 (0.85 to 2.00) 1.03 (0.73 to 1.45)
  Unknown 1.17 (0.83 to 1.66) 1.22 (1.01 to 1.48) 1.21 (1.04 to 1.41) 1.20 (1.07 to 1.33)
AUROC 0.7962 0.7961 0.7935 0.7902
AIC 13 382.17 42 896.17 69 852.12 1 38 058.2
Model 2 Ever before score 1.59 (1.52 to 1.67) 1.61 (1.56 to 1.65) 1.60 (1.56 to 1.63) 1.57 (1.55 to 1.60)
Age 1.12 (1.11 to 1.13) 1.12 (1.11 to 1.12) 1.12 (1.11 to 1.12) 1.12 (1.11 to 1.12)
Gender (F) 0.81 (0.69 to 0.95) 0.76 (0.70 to 0.83) 0.76 (0.71 to 0.82) 0.76 (0.72 to 0.80)
IMD (vs least deprived)         
  Q5 (most deprived) 1.33 (1.02 to 1.73) 1.48 (1.28 to 1.72) 1.47 (1.31 to 1.65) 1.59 (1.46 to 1.72)
Ethnicity (vs white)         
  Black 2.26 (1.16 to 4.39) 1.67 (1.08 to 2.57) 1.43 (0.99 to 2.07) 1.16 0.87 to 1.56)
  Asian 1.65 (0.97 to 2.80) 1.49 (1.09 to 2.06) 1.43 (1.11 to 1.84) 1.15 0.94 to 1.42)
  Mixed – 1.81 (0.75 to 4.36) 1.57 (0.75 to 3.29) 0.79 0.37 to 1.65)
  Other 1.73 (0.77 to 3.87) 1.35 (0.80 to 2.29) 1.27 (0.83 to 1.96) 1.05 0.74 to 1.49)
  Unknown 1.49 (1.06 to 2.12) 1.59 (1.31 to 1.93) 1.54 (1.32 to 1.80) 1.48 (1.32 to 1.65)
AUROC 0.8030 0.8041 0.8024 0.8010
AIC 13 091.66 41 971.42 68 465.3 AIC=1 35 778.9
Model 3 10- year before score 1.59 (1.51 to 1.67) 1.59 (1.55 to 1.64) 1.58 (1.54 to 1.62) 1.55 (1.53 to 1.58)
Age 1.12 (1.11 to 1.13) 1.12 (1.12 to 1.13) 1.12 (1.12 to 1.12) 1.12 (1.12 to 1.12)
Gender (F) 0.81 (0.69 to 0.95) 0.75 (0.69 to 0.83) 0.75 (0.70 to 0.81) 0.75 (0.71 to 0.79)
IMD (vs least deprived)
  Q5 (most deprived) 1.32 (1.01 to 1.73) 1.47 (1.27 to 1.71) 1.46 (1.30 to 1.64) 1.57 (1.45 to 1.71)
Ethnicity (vs white)         
  Black 2.13 (1.19 to 4.50) 1.72 (1.11 to 2.65) 1.48 (1.03 to 2.14) 1.20 1.89 to 1.65)
  Asian 1.74 (1.02 to 2.95) 1.58 (1.15 to 2.17) 1.51 (1.17 to 1.95) 1.20 0.98 to 1.47)
  Mixed – 1.81 (0.75 to 4.36) 1.57 (0.75 to 3.30) 0.79 0.38 to 1.66)
  Other 1.73 (0.77 to 3.86) 1.38 (0.81 to 2.33) 1.28 (0.83 to 1.97) 1.05 0.74 to 1.48)
  Unknown 1.47 (1.04 to 2.08) 1.55 (1.28 to 1.88) 1.51 (1.29 to 1.75) 1.45 (1.30 to 1.61)
AUROC 0.8032 0.8039 0.800 0.8000
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over corresponding all- cause outcomes. When catego-
rised, higher severity category levels were associated 
with increasing risks of hospitalisation and mortality 
(table 5 and figure 2). Severity score- only models using 
the training and validation dataset were also fitted and 
the AUROCs were up to 0.70 as summarised in online 
supplemental table S10. Models without IMD quintiles 
are summarised in online supplemental table S11. The 
performed calibration tests showed good calibration of 
the severity scores (online supplemental tables S12 and 
S13, figure 1 vs online supplemental figures S2 and S3). 
Testing for proportional hazards indicated the assump-
tions held true (online supplemental figures S4–S8). 
The validation dataset findings were all similar to those 
in the training dataset (online supplemental tables 
S14–S18 and figures S9–S12). The study methods and 
main findings are outlined in summary online supple-
mental figures S13 and S14.
DISCUSSION
Main findings
In this long- term retrospective cohort study, we present 
a contemporary and validated scoring system grading 
CVD severity in people with CHD. Our developed base-
line and longitudinal severity scores provide important 
prognostic information for all- cause and cause- specific 
hospitalisation and mortality events in people with CHD 
that had marginal but statistically significant better 
predictive value in comparison with that provided by 
models only including sociodemographic variables. 
Each one- unit increase in disease severity was associated 
with elevated risks for all- cause mortality by 41%, CV/
diabetes mortality by 59% and any cause hospitalisation 
by 27%.
Comparison with other studies
A few observational studies have assessed disease severity 
in people with CHD using routine primary care EHRs, 
while some studies used data derived from secondary or 
tertiary care settings to assess severity of CHD for various 
research questions.19 33–35 However, the majority of prior 
studies assessing the severity of CHD were reporting risk 
scores based on the anatomical severity and character-
istics of CAD, and they are used to assess the prognosis 
following revascularisation interventions, for example, 
SYNTAX and Gensini scores,11 12 but do not provide 
information for the majority of patients with CHD not 
undergoing these interventions.
Some symptom- based tools were reportedly used to 
categorise disease severity.36–38 However, the majority of 
people with CHD are asymptomatic, which may limit 
the application of such tools to the wider population 
of patients with CHD in clinical practice. Other studies 
classified CHD severity either by the CHD onset type 
(myocardial infarction, unstable or stable angina catego-
ries),39–41 or the number of hospitalisation events.42
One observational study based on primary care data in 
Italy, estimated the positive predictive value for automated 
identification and severity assessment of four chronic 
conditions, including CHD.10 The disease severity in 300 
people with CHD was categorised into five levels based 
on the evidence of presence/absence of heart failure and 
coronary angioplasty. They reported a good agreement 
score (Cohen’s kappa=0.69) between the automated 
algorithm and the general practitioner’s assessment on 
the CHD severity level.
In our study, the new CV severity score was developed 
in a larger cohort, and it included heart failure and 
coronary procedures besides 18 additional severity indi-
cators. Our score can be more applicable to a broader 
Predictor(s) 1 year 3 years 5 years 10 years
Model 4 5- year before score 1.55 (1.46 to 1.65) 1.56 (1.51 to 1.62) 1.56 (1.52 to 1.60) 1.52 (1.49 to 1.55)
Age 1.12 (1.11 to 1.13) 1.13 (1.12 to 1.13) 1.12 (1.12 to 1.13) 1.12 (1.12 to 1.12)
Gender (F) 0.79 (0.67 to 0.93) 0.74 (0.68 to 0.81) 0.74 (0.69 to 0.79) 0.74 (0.71 to 0.78)
IMD (vs least deprived)         
  Q5 (most deprived) 1.32 (1.01 to 1.73) 1.48 (1.27 to 1.71) 1.46 (1.30 to 1.64) 1.58 (1.45 to 1.71)
Ethnicity (vs White)         
  Black 2.33 (1.20 to 4.54) 1.78 (1.16 to 2.75) 1.57 (1.08 to 2.26) 1.27 (0.95 to 1.71)
  Asian 1.78 (1.05 to 3.03) 1.62 (1.18 to 2.22) 1.55 (1.20 to 2.00) 1.24 1.01 to 1.52)
  Mixed – 1.83 (0.76 to 4.41) 1.58 (0.75 to 3.31) 0.79 0.38 to 1.66)
  Other 1.75 (0.78 to 3.92) 1.40 (0.82 to 2.36) 1.30 (0.85 to 2.00) 1.06 0.75 to 1.49)
  Unknown 1.41 (1.00 to 2.00) 1.48 (1.22 to 1.80) 1.45 (1.25 to 1.69) 1.40 (1.26 to 1.56)
AUROC 0.8024 0.8030 0.8010 0.7983
AIC 13 203.79 42 321.24 68 960.76 1 36 620.3
AIC, Akaike information criterion; AUROC, area under a receiver operating characteristics curve; CV, cardiovascular; DM, diabetes mellitus; 
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Table 3 Competing risk analysis models for 1- year any- cause hospitalisation and 1- year CV/DM- related hospitalisation 
(competed by all- cause death) using baseline scores – training dataset
Predictor(s)
1- year any- cause hospitalisation
1- year
CV/DM hospitalisation
SHR (95% CI) SHR (95% CI)
Model 1 Age 1.02 (1.02 to 1.02) 1.02 (1.02 to 1.02)
Gender (F) 0.68 (0.67 to 0.70) 0.57 (0.55 to 0.58)
IMD (vs least deprived)
  Q5 (most deprived) 1.07 (1.04 to 1.11) 1.05 (1.01 to 1.09)
Ethnicity (vs white)
  Black 0.93 (0.84 to 1.03) 0.74 (0.64 to 0.84)
  Asian 1.42 (1.34 to 1.50) 1.53 (1.43 to 1.63)
  Mixed 0.97 (0.81 to 1.17) 1.05 (0.85 to 1.30)
  Other 1.01 (0.91 to 1.13) 1.0 (0.87 to 1.14)
  Unknown 0.22 (0.21 to 0.24) 0.22 (0.20 to 0.24)
AIC 995 523.4 704 241.7
Model 2 Ever before score 1.27 (1.26 to 1.28) 1.37 (1.36 to 1.38)
Age 1.01 (1.01 to 1.01) 1.01 (1.01 to 1.01)
Gender (F) 0.71 (0.70 to 0.73) 0.60 (0.59 to 0.62)
IMD (vs least deprived)
  Q5 (most deprived) 1.05 (1.02 to 1.08) 1.02 (0.98 to 1.05)
Ethnicity (vs white)
  Black 0.88 (0.79 to 0.97) 0.68 (0.57 to 0.78)
  Asian 1.33 (1.25 to 1.40) 1.39 (1.31 to 1.49)
  Mixed 0.95 (0.79 to 1.14) 1.03 (0.84 to 1.27)
  Other 1.00 (0.90 to 1.12) 0.96 (0.84 to 1.10)
  Unknown 0.24 (0.22 to 0.26) 0.24 (0.22 to 0.27)
AIC 992 032.8 699 582.5
Model 3 10- year before score 1.28 (1.27 to 1.29) 1.39 (1.37 to 1.40)
Age 1.01 (1.01 to 1.01) 1.01 (1.01 to 1.01)
Gender (F) 0.72 (0.70 to 0.73) 0.60 (0.59 to 0.62)
IMD (vs least deprived)
  Q5 (most deprived) 1.05 (1.02 to 1.08) 1.01 (0.98 to 1.05)
Ethnicity (vs white)
  Black 0.88 (0.80 to 0.97) 0.68 (0.60 to 0.78)
  Asian 1.34 (1.26 to 1.42) 1.40 (1.32 to 1.51)
  Mixed 0.96 (0.80 to 1.15) 1.04 (0.84 to 1.28)
  Other 1.00 (0.90 to 1.12) 0.96 (0.84 to 1.10)
  Unknown 0.24 (0.22 to 0.26) 0.24 (0.22 to 0.27)
AIC 992 096.3 699 635.1
Model 4 5- year before score 1.30 (1.29 to 1.31) 1.41 (1.40 to 1.43)
Age 1.01 (1.01 to 1.01) 1.01 (1.01 to 1.01)
Gender (F) 0.71 (0.70 to 0.73) 0.60 (0.59 to 0.62)
IMD (vs least deprived)
  Q5 (most deprived) 1.05 (1.02 to 1.08) 1.02 (0.98 to 1.05)
Ethnicity (vs white)
  Black 0.89 (0.80 to 0.98) 0.69 (0.60 to 0.79)
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population of patients with CHD than existing scores. 
Current scores either focus on small and highly selected 
groups of patients undergoing coronary procedures 
(eg, SYNTAX)11 or define CHD severity in an overall 
simplistic approach by syndrome that does not take into 
account the close pathophysiological links between some 
of the included CV conditions thereby possibly reducing 
clinical relevance. In addition, we included clinically rele-
vant severity indicators (such as diabetes which contrib-
utes to CHD severity42), and we evaluated the association 
between severity score and health outcomes. CV severity 
indicators may need revising in a few years as newer tests 
and measures become available in primary care setting. 
Therefore, future studies can include additional severity 
indicators, subject to their availability and well recording 
in primary care data, such as the coronary calcium score, 
ankle- brachial index test, B- type natriuretic peptide 
(BNP) or N- terminal pro BNP (NT- pro- BNP) levels 
and high- sensitivity C reactive protein (hs- CRP) levels. 
The inclusion of social deprivation data highlights the 
advantage of used EHRs driven from national health-
care systems, such as the NHS, as patients represent all 
social levels unlike what would be recorded from private 
medical systems. While social deprivation levels may not 
be directly compared with other populations, under-
standing the underlying domains and the allocation of 
patients into categories of least deprived versus most 
deprived may allow for a rough comparison with other 
populations as appropriate.
Potential benefits to clinical practice
People with CHD are mainly managed in primary care 
settings. Our severity measure is based on medical data 
routinely collected in general practice visits, which 
indicates its potential usefulness in risk stratification of 
people with CHD. The score calculation method can be 
first implemented as a simple table (online supplemental 
table S2) to enable clinicians estimate patient’s CVD 
severity at baseline and over time. This can help iden-
tify people with CHD at a greater risk for adverse health 
outcomes, which informs advanced decision making. On 
a wider context, our algorithm is reproducible for other 
long- term conditions managed in primary care.
Predictor(s)
1- year any- cause hospitalisation
1- year
CV/DM hospitalisation
SHR (95% CI) SHR (95% CI)
    Mixed 0.96 (0.80 to 1.16) 1.04 (0.85 to 1.29)
  Other 1.00 (0.90 to 1.12) 0.97 (0.85 to 1.11)
  Unknown 0.24 (0.22 to 0.26) 0.24 (0.22 to 0.27)
AIC 992 244.2 699 853.5
AIC, Akaike information criterion; CV, cardiovascular; DM, diabetes mellitus; IMD, Index of multiple deprivation; SHR, subhazard ratio.
Table 3 Continued
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Study strengths and limitations
The strengths of our study include: first, we analysed a 
large cohort of patients with CHD to develop and validate 
the severity scores, derived from a high- quality EHR data-
base. Second, our models were based on baseline and 
longitudinal severity scores and included important socio-
demographic variables, including social deprivation and 
ethnicity. Third, we compared the added predictive value 
of the developed score in comparison with that provided 
by models only including sociodemographic variables in 
all outcomes. In addition to all- cause mortality, which 
allows for a broad perspective of the burden of CHD, 
and hospital admissions, our measured outcomes also 
included CV and diabetes- related events. Fourth, we used 
longer term follow- up different from the available 30- day 
and 6- month risk scores. Finally, we invited people with 
CHD who provided their feedback on different aspects 
of the study.
Our study has several limitations. First, there is a risk 
of misclassifying the identified cases and severity indica-
tors. However, the high validity of CVD diagnoses using 
CPRD data has been reported previously.23 43 Second, 
other important severity indicators may have been 
missed since they are not available or routinely recorded 
in primary care, such as NT- pro- BNP levels or ankle- 
brachial index. However, using routinely available data 
allows the creation of a tool that can be applied to 
primary care and relevant research with EHRs. Third, by 
the nature of the cohort design, we missed non- survivors 
(people who died due to the first event). Fourth, as our 
validation was based on replicated analyses in a separate 
dataset (internal validation), future study is needed for 
external validation in an independent database before 
reporting the complete clinical utility and implications 
of our score. However, we observed very similar results 
when we compared our approach to two additional vali-
dation analyses based on postestimation from training 
dataset using CV mortality outcome.26 44 Fifth, although 
the selection of binary weighting system is practical for 
replication of the score in clinical practice, future studies 
examining the risks of these indicators considering their 
different levels of severity, that is, as severity- weighted 
indicators are required. Finally, generalisability to other 
healthcare systems and/or other ethnic groups may be 
limited, but we believe a similar algorithm can be used in 
those circumstances given that the severity indicators are 
collected in routine primary care visits.
CONCLUSIONS
While CHD is associated with multiple morbidities and 
a leading cause of mortality worldwide,3 severity meas-
ures for CHD based on primary care data are limited and 
needed. This study provides a contemporary measure 
of CVD severity derived by routine primary care EHRs 
for people with CHD, which showed high predictive 
value of hospitalisation and death outcomes. Our find-
ings indicate that an increase in CVD severity in adult 
Table 5 Adjusted 1- year and 3- year HR or SHR (95% CI) for mortality and hospitalisation outcomes by the cardiovascular 
severity score category
Outcome




severity High severity No severity Low severity
Moderate 
severity High severity
1- year all- cause 
mortality
Reference 1.49 (1.22 to 1.81) 3.03 (2.46 to 3.72) 5.64 (4.44 to 7.15) Reference 1.25 (0.87 to 1.80) 2.62 (1.80 to 3.82) 4.76 (3.06 to 7.40)
AUROC=0.7899 AUROC=0.7881
3- year all- cause 
mortality
Reference 1.40 (1.26 to 1.54) 2.90 (2.61 to 3.22) 5.34 (4.71 to 6.04) Reference 1.20 (1.00 to 1.45) 2.17 (1.78 to 2.63) 4.63 (3.67 to 5.84)
AUROC=0.7863 AUROC=0.7857
1- year CV/diabetes 
mortality
Reference 1.58 (1.06 to 2.35) 4.09 (2.73 to 6.11) 9.38 (6.04 to 14.54) Reference 1.12 (0.58 to 2.18) 3.32 (1.69 to 6.49) 6.53 (3.05 to 13.97)
AUROC=0.8003 AUROC=0.7951
3- year CV/diabetes 
mortality
Reference 1.95 (1.53 to 2.48) 5.46 (4.28 to 6.96) 11.75 (9.00 to 
15.33)
Reference 1.14 (0.78 to 1.68) 2.96 (2.00 to 4.38) 8.53 (5.54 to 13.12)
AUROC=0.8038 AUROC=0.7953
1- year any 
hospitalisation*
Reference 1.62 (1.57 to 1.67) 2.47 (2.38 to 2.56) 3.47 (3.27 to 3.68) Reference 1.65 (1.55 to 1.76) 2.51 (2.33 to 2.70) 3.31 (2.94 to 3.73)
AIC=992 385.1 AIC=2 19 586.1
3- year any 
hospitalisation*
Reference 1.41 (1.38 to 1.44) 2.10 (2.04 to 2.15) 2.85 (2.73 to 2.99) Reference 1.41 (1.35 to 1.47) 2.05 (1.95 to 2.15) 2.72 (2.48 to 2.97)
AIC=1 965 741 AIC=4 33 770.1
1- year CV/diabetes 
hospitalisation*
Reference 2.11 (2.02 to 2.20) 3.71 (3.54 to 3.89) 5.51 (5.15 to 5.91) Reference 2.15 (1.98 to 2.34) 3.73 (3.39 to 4.10) 5.26 (4.59 to 6.04)
AIC=6 99 933.1 AIC=1 55 656.5
3- year CV/diabetes 
hospitalisation *
Reference 2.03 (1.97 to 2.10) 3.79 (3.66 to 3.92) 5.63 (5.34 to 5.92) Reference 2.04 (1.92 to 2.17) 3.73 (3.48 to 4.00) 5.45 (4.93 to 6.03)
AIC=1 262 175 AIC=280 208.9
Severity score categories: no severity: score=0 (referent category); low severity: score=1–2; moderate severity: score=3–4; high severity: score ≥5.
All results are adjusted for age, gender, IMD and ethnicity (model 2).
*SHR: subhazard ratio estimated for the competing risk models for risk for hospitalisation.
AIC, Akaike information criterion; AUROC, area under a Receiver Operating Characteristics curve; CV, cardiovascular; IMD, index of multiple deprivation. copyright.
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people with CHD was associated with higher risks for all- 
cause and CV- specific hospital admissions and mortality 
outcomes. There is underused informative longitudinal, 
multimorbid structure in routine clinical records and 
our paper focus on the wider CV spectrum around CHD. 
Disease- specific severity tools have direct impact on clin-
ical practice, by stratifying care according to disease 
severity, and can help inform service planning and risk 
stratification for precision medicine. Future research on 
external validation of the severity score is needed before 
reporting its complete clinical utility and implications.
Author affiliations
1NIHR School for Primary Care Research, Centre for Primary Care and Health 
Services Research, Manchester Academic Health Science Centre (MAHSC), The 
University of Manchester, Manchester, UK
2Division of Population Health, Health Services Research and Primary Care, School 
of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic 
Health Science Centre (MAHSC), The University of Manchester, Manchester, UK
3Keele Cardiovascular Research Group, Centre for Prognosis Research, School of 
Primary, Community and Social Care, Keele University, Stoke- on- Trent, UK
4Division of Pharmacy and Optometry, School of Health Sciences, Faculty of Biology, 
Medicine and Health, Manchester Academic Health Science Centre (MAHSC), The 
University of Manchester, Manchester, UK
5NIHR Greater Manchester Patient Safety Translational Research Centre, The 
University of Manchester, Manchester, UK
6NIHR Manchester Biomedical Research Centre, Manchester Academic Health 
Science Centre (MAHSC), Manchester, UK
7Division of Diabetes, Endocrinology and Gastroenterology, School of Medical 
Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health 
Science Centre (MAHSC), The University of Manchester, Manchester, UK
8Diabetes, Endocrinology and Metabolism Centre, Manchester University NHS 
Foundation Trust, Manchester Academic Health Science Centre (MAHSC), 
Manchester, UK
9Division of Primary Care and Public Health, Brighton and Sussex Medical School, 
University of Brighton, Brighton, UK
10Centre for Academic Primary Care, Population Health Sciences, Bristol Medical 
School, University of Bristol, Bristol, UK
11School of Primary, Community and Social Care, Faculty of Medicine and Health 
Sciences, Keele University, Staffordshire, UK
12Primary Care Stratified Medicine (PRISM) Research Group, Division of Primary 
Care, School of Medicine, University of Nottingham, Nottingham, UK
13Statistical Decision Sciences, Cardiovascular and Metabolism, Janssen Research 
and Development, High Wycombe, UK
14Nuffield Department of Primary Care Health Sciences, University of Oxford, 
Oxford, UK
15Institute of Population Health Sciences, University of Liverpool, Liverpool, UK
16Division of Informatics, Imaging and Data Sciences, School of Health Sciences, 
Faculty of Biology, Medicine and Health, Manchester Academic Health Science 
Centre (MAHSC), The University of Manchester, Manchester, UK
17Centre for Biostatistics, School of Health Sciences, Faculty of Biology, Medicine 
and Health, Manchester Academic Health Science Centre (MAHSC), The University 
of Manchester, Manchester, UK
Twitter Mamas A Mamas @mmamas1973
Acknowledgements The authors would like to thank Mr Manoj Mistry and Mrs 
Angela Ruddock for their invaluable insight codeveloping and cofacilitating the 
patient and public involvement and engagement meeting and all participants for 
their time and important feedback. This study is based in part on data from the 
Clinical Practice Research Datalink (CPRD) obtained under licence from the UK 
Medicines and Healthcare products Regulatory Agency (MHRA). The study protocol 
was approved by the CPRD Independent Scientific Advisory Committee (ISAC). The 
data are provided by patients and collected by the NHS as part of their care and 
support. These data included ONS and HES data. The interpretation and conclusions 
contained in this study are those of the author/s alone. 'Copyright © (2018), 
re- used with the permission of The Health & Social Care Information Centre. All 
rights reserved'. Some of the findings were presented at the National Institute for 
Health Research School for Primary Care Research Showcase, November 2019, 
London, UK; and the Health Services Research UK Conference, July 2020 (Online).
Contributors EK, MM and SZ designed the study. SZ extracted and analysed 
the data and drafted the manuscript. MM, DR and EK critically revised the initial 
versions, and all authors contributed to interpretation of data and revised the paper 
for important intellectual content. All authors agreed on the final version of the 
paper before submission. SZ is the guarantor of the paper.
Funding This study is funded by the National Institute for Health Research (NIHR) 
School for Primary Care Research (NIHR SPCR – grant number 331).
Disclaimer The views expressed are those of the authors and not necessarily 
those of the NIHR or the Department of Health and Social Care. The funder 
of the study had no role in study design, data collection, data analysis, data 
interpretation or writing of the report. The lead author had full access to the data 
in the study, takes responsibility for its integrity and the data analysis and had final 
responsibility for the decision to submit for publication.
Competing interests DMA reports research grants from Abbvie, Almirall, Celgene, 
Eli Lilly, Novartis, UCB and the Leo Foundation and is funded by the NIHR Greater 
Manchester Patient Safety Translational Research Centre, the NIHR School for 
Primary Care Research, and the NIHR Manchester Biomedical Research Centre. 
MKR has received educational grant support from MSD and Novo Nordisk; has 
modest stock ownership in GSK; and has consulted for Roche. CS reports grants 
from NIHR School for Primary Care Research during the conduct of the study, is 
partially supported by NHS ARC West and is an NIHR Senior Investigator. CDM 
is funded by the NIHR Collaborations for Leadership in Applied Health Research 
and Care West Midlands, the NIHR School for Primary Care Research and a NIHR 
Research Professorship in General Practice (NIHR- RP-2014-04-026). He has 
provided support for a Bristol Myer Squibb non- pharmacological Atrial Fibrillation 
study (funding to School). NQ reports grants from the NIHR SPCR and NIHR HTA, 
during the conduct of the study. SFW is an employee of Janssen R NIHR Senior 
Investigator grant. NP’s time was partially funded by the NIHR Manchester 
Biomedical Research Centre. Other coauthors have no disclosures.
Patient consent for publication Not required.
Ethics approval The study was approved by the Independent Scientific Advisory 
Committee (ISAC) for MHRA Database Research (protocol number: 17_168). 
Generic ethical approval for observational research using CPRD with approval 
from ISAC has been granted by a Health Research Authority (HRA) Research Ethics 
Committee (East Midlands—Derby, REC reference number 05/MRE04/87).
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Clinical code lists are available from  clinicalcodes. 
org. Electronic health records are, by definition, considered sensitive data in the UK 
by the Data Protection Act and cannot be shared via public deposition because of 
information governance restriction in place to protect patient confidentiality. Access 
to data is available only once approval has been obtained through the individual 
constituent entities controlling access to the data. The primary care data can be 
requested via application to the Clinical Practice Research Datalink, secondary care 
data can be requested via application to the Hospital Episode Statistics from the 
UK Health and Social Care Information Centre, and mortality data are available by 
application to the UK Office for National Statistics.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
ORCID iDs
Salwa S Zghebi http:// orcid. org/ 0000- 0002- 7978- 1094
Mamas A Mamas http:// orcid. org/ 0000- 0001- 9241- 8890
Nadeem Qureshi http:// orcid. org/ 0000- 0003- 4909- 0644
Evangelos Kontopantelis http:// orcid. org/ 0000- 0001- 6450- 5815
REFERENCES
 1 World Health Organization (WHO) media centre. Cardiovascular 
diseases (CVDs). Secondary Cardiovascular diseases (CVDs) [Fact 
sheet], 2017. Available: https://www. who. int/ news- room/ fact- sheets/ 
detail/ cardiovascular- diseases-( cvds)
copyright.
 on A














13Zghebi SS, et al. Open Heart 2021;8:e001498. doi:10.1136/openhrt-2020-001498
Coronary artery disease
 2 British Heart Foundation. BHF UK Factsheet November 2018. 
Secondary BHF UK Factsheet, 2018. Available: https://www. bhf. org. 
uk/ what- we- do/ our- research/ heart- statistics
 3 Sanchis- Gomar F, Perez- Quilis C, Leischik R, et al. Epidemiology of 
coronary heart disease and acute coronary syndrome. Ann Transl 
Med 2016;4:256.
 4 Bhatnagar P, Wickramasinghe K, Wilkins E, et al. Trends in 
the epidemiology of cardiovascular disease in the UK. Heart 
2016;102:1945–52.
 5 Ginghina C, Bejan I, Ceck CD. Modern risk stratification in coronary 
heart disease. J Med Life 2011;4:377–86.
 6 Hippisley- Cox J, Coupland C, Brindle P. Development and 
validation of QRISK3 risk prediction algorithms to estimate future 
risk of cardiovascular disease: prospective cohort study. BMJ 
2017;357:j2099.
 7 Wilson PW, D'Agostino RB, Levy D, et al. Prediction of 
coronary heart disease using risk factor categories. Circulation 
1998;97:1837–47.
 8 Zghebi SS, Rutter MK, Ashcroft DM, et al. Using electronic health 
records to quantify and stratify the severity of type 2 diabetes in 
primary care in England: rationale and cohort study design. BMJ 
Open 2018;8:e020926.
 9 Gambert S. Disease Severity. In: Gellman MD, Turner JR, eds. 
Encyclopedia of behavioral medicine. New York, NY: Springer, 2013.
 10 Gini R, Schuemie MJ, Mazzaglia G, et al. Automatic identification 
of type 2 diabetes, hypertension, ischaemic heart disease, heart 
failure and their levels of severity from Italian general practitioners' 
electronic medical records: a validation study. BMJ Open 
2016;6:e012413.
 11 Syntax Score Working Group. The SYNTAX score. secondary the 
SYNTAX score, 2016. Available: http://www. syntaxscore. com/
 12 Gensini GG. A more meaningful scoring system for determining the 
severity of coronary heart disease. Am J Cardiol 1983;51:606.
 13 Vivekananthan DP, Blackstone EH, Pothier CE, et al. Heart rate 
recovery after exercise is a predictor of mortality, independent of 
the angiographic severity of coronary disease. J Am Coll Cardiol 
2003;42:831–8.
 14 Cury RC, Abbara S, Achenbach S, et al. Coronary Artery Disease 
- Reporting and Data System (CAD- RADS): An Expert Consensus 
Document of SCCT, ACR and NASCI: Endorsed by the ACC. JACC 
Cardiovasc Imaging 2016;9:1099–113.
 15 Smith LR, Harrell FE, Rankin JS, et al. Determinants of early versus 
late cardiac death in patients undergoing coronary artery bypass 
graft surgery. Circulation 1991;84:245–53.
 16 Helmy H, Abdel- Galeel A, Taha Kishk Y, et al. Correlation of 
corrected QT dispersion with the severity of coronary artery disease 
detected by SYNTAX score in non- diabetic patients with STEMI. 
Egypt Heart J 2017;69:111–7.
 17 Langroudi TF, Haybar H, Parsa SA, et al. The severity of coronary 
artery disease was not associated with non- alcoholic fatty liver 
disease in a series of 264 non- diabetic patients who underwent 
coronary angiography. Rom J Intern Med 2018;56:167–72.
 18 Bouzidi N, Sahli S, Khlifi L. Lipid profile variables and prediction of 
the severity of coronary artery disease in Tunisian type 2 diabetic 
patients. Int J Pharm Sci Rev Res 2017.
 19 Srinivasan MP, Kamath PK, Bhat NM, et al. Manipal diabetes 
coronary artery severity score. Diabetes Metab Syndr 2017;11 Suppl 
1:S33–7.
 20 Herrett E, Gallagher AM, Bhaskaran K, et al. Data resource profile: 
Clinical Practice Research Datalink (CPRD). Int J Epidemiol 
2015;44:827–36.
 21 Kontopantelis E, Stevens RJ, Helms PJ, et al. Spatial distribution of 
clinical computer systems in primary care in England in 2016 and 
implications for primary care electronic medical record databases: a 
cross- sectional population study. BMJ Open 2018;8:e020738.
 22 Department for Communities and Local Government. The English 
indices of deprivation 2015. Secondary the English indices of 
deprivation, 2015. Available: https:// assets. publishing. service. gov. 
uk/ government/ uploads/ system/ uploads/ attachment_ data/ file/ 
465791/ English_ Indices_ of_ Deprivation_ 2015_-_ Statistical_ Release. 
pdf
 23 Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within 
the general practice research database: a systematic review. Br J 
Gen Pract 2010;60:e128–36.
 24 Olier I, Springate DA, Ashcroft DM, et al. Modelling conditions and 
health care processes in electronic health records: an application 
to severe mental illness with the clinical practice research Datalink. 
PLoS One 2016;11:e0146715.
 25 Heagerty PJ, Zheng Y. Survival model predictive accuracy and ROC 
curves. Biometrics 2005;61:92–105.
 26 Royston P, Altman DG. External validation of a Cox prognostic 
model: principles and methods. BMC Med Res Methodol 
2013;13:33.
 27 Royston P. Tools for checking calibration of a Cox model in external 
validation: prediction of population- averaged survival curves based 
on risk groups. Stata J 2015;15:275–91.
 28 StataCorp LLC. Stata Base Reference Manual - Release 15. 
Secondary Stata Base Reference Manual - Release 15 2017, 2017. 
Available: https://www. stata. com/ manuals/ r. pdf
 29 Royston P, Lambert PC. Prognostic models. In: Flexible parametric 
survival analysis using Stata: beyond the Cox model. Texas, USA: 
Stata Press, 2011: 152–3.
 30 Caetano SJ, Sonpavde G, Pond GR. C- statistic: A brief explanation 
of its construction, interpretation and limitations. Eur J Cancer 
2018;90:130–2.
 31 StataCorp. Stata 15 survival analysis reference manual. Secondary 
Stata 15 survival analysis reference manual, 2017. Available: https://
www. stata. com/ manuals/ st. pdf
 32 StataCorp LLC. Stata statistical software. Secondary stata statistical 
software, 2018. Available: https://www. stata. com/
 33 Srinivasan M, Bhat N, Kamath P, et al. Risk factors for complex 
and severe coronary artery disease in type 2 diabetes mellitus. J 
Cardiovasc Dis Res 2017;8:19–23.
 34 Özcan C, Deleskog A, Schjerning Olsen A- M, et al. Coronary artery 
disease severity and long- term cardiovascular risk in patients with 
myocardial infarction: a Danish nationwide register- based cohort 
study. Eur Heart J Cardiovasc Pharmacother 2018;4:25–35.
 35 Shenoy R, Bhat R, Srinivasan M. Correlation between insulin 
resistance and severity of coronary artery disease in non- diabetes. 
Asian J Pharm Clin Res 2016;9:331–3.
 36 Mancini GBJ, Boden WE, Brooks MM, et al. Impact of treatment 
strategies on outcomes in patients with stable coronary artery 
disease and type 2 diabetes mellitus according to presenting angina 
severity: a pooled analysis of three federally- funded randomized 
trials. Atherosclerosis 2018;277:186–94.
 37 Schopfer DW, Regan M, Heidenreich PA, et al. Depressive 
symptoms, cardiac disease severity, and functional status in patients 
with coronary artery disease (from the heart and soul study). Am J 
Cardiol 2016;118:1287–92.
 38 Sudzinova A, Nagyova I, Studencan M, et al. Roma coronary heart 
disease patients have more medical risk factors and greater severity 
of coronary heart disease than non- Roma. Int J Public Health 
2013;58:409–15.
 39 Liu C, Yang Y, Peng D, et al. Hyperhomocysteinemia as a metabolic 
disorder parameter is independently associated with the severity of 
coronary heart disease. Saudi Med J 2015;36:839–46.
 40 Katsouras CS, Karabina SA, Tambaki AP, et al. Serum lipoprotein(a) 
concentrations and apolipoprotein(a) isoforms: association with 
the severity of clinical presentation in patients with coronary heart 
disease. J Cardiovasc Risk 2001;8:311–7.
 41 Chotchaeva FR, Balatskiy AV, Samokhodskaya LM. Association 
between T- cadherin gene (CDH13) variants and severity of 
coronary heart disease manifestation. Int J Clin Exp Med 
2016;9:4059–8353.
 42 Javidi D, Gharaei B, Fateh S. The contribution of diabetes mellitus 
per se to the severity of coronary artery disease. Cardiovasc J S Afr 
2005;16:246–8.
 43 Maru S, Koch GG, Stender M, et al. Antidiabetic drugs and heart 
failure risk in patients with type 2 diabetes in the U.K. primary care 
setting. Diabetes Care 2005;28:20–6.
 44 Newson RB. Comparing the Predictive Powers of Survival Models 
Using Harrell’s C or Somers’ D. Stata J 2010;10:339–58.
copyright.
 on A









eart: first published as 10.1136/openhrt-2020-001498 on 20 A
pril 2021. D
ow
nloaded from
 
